Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort

被引：0
|
作者：
Ville Kukko
Antti Kaipia
Kirsi Talala
Kimmo Taari
Teuvo L. J. Tammela
Anssi Auvinen
Teemu J. Murtola
机构：
[1] University of Tampere,Faculty of Medicine and Life Sciences
[2] Tampere University Hospital,Department of Urology
[3] Finnish Cancer Registry,Department of Urology
[4] University of Helsinki and Helsinki University Hospital,Faculty of Social Sciences
[5] University of Tampere,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：373 / 378
页数：5
相关论文
共 50 条
  • [31] Changes in diagnosis rate and treatment trends of benign prostatic hyperplasia in Korea: A nationwide population-based cohort study
    Kim, Do Kyung
    Park, Jae Joon
    Yang, Won Jae
    Doo, Seung Whan
    Kim, Jae Heon
    Song, Yun Seob
    PROSTATE INTERNATIONAL, 2021, 9 (04) : 215 - 220
  • [32] Healthcare utilization and costs in patients with benign prostatic hyperplasia: a population-based study
    Chung, Shiu-Dong
    Tzeng, Ya-Mei
    Lin, Herng-Ching
    Huang, Chao-Yuan
    ASIAN JOURNAL OF ANDROLOGY, 2016, 18 (06) : 942 - 945
  • [33] Medical management of benign prostatic hyperplasia: Results from a population-based study
    Bishr, Mohamed
    Boehm, Katharina
    Trudeau, Vincent
    Tian, Zhe
    Dell'Oglio, Paolo
    Schiffmann, Jonas
    Jeldres, Claudio
    Sun, Maxine
    Shariat, Sharokh F.
    Graefen, Markus
    Saad, Fred
    Karakiewicz, Pierre I.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2016, 10 (1-2): : 55 - 59
  • [34] Five-alpha reductase inhibitor use and risk of kidney and bladder cancer in men with benign prostatic hyperplasia: A population-based cohort study
    Doherty, Niamh
    Cardwell, Christopher
    Murchie, Peter
    Hill, Christopher
    Azoulay, Laurent
    Hicks, Blanaid
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 138 - 139
  • [35] Association of alpha-1-adrenergic antagonist use with the risk of gout development in benign prostatic hyperplasia patients: a population-based cohort study
    Hsu, Wei-Hung
    Lai, Jung-Nien
    Lin, Cheng-Li
    Loh, Ching-Hui
    Huang, Huei-Kai
    Huang, Liang-Kai
    FAMILY PRACTICE, 2022, 39 (03) : 426 - 431
  • [36] Fall risk related to subtype-specific alpha-antagonists for benign prostatic hyperplasia: a nationwide Korean population-based cohort study
    Jae-Hyun Seo
    Jae Sang Han
    Yunhee Lee
    Jun-Pyo Myong
    U-Syn Ha
    World Journal of Urology, 2022, 40 : 3043 - 3048
  • [37] Fall risk related to subtype-specific alpha-antagonists for benign prostatic hyperplasia: a nationwide Korean population-based cohort study
    Seo, Jae-Hyun
    Han, Jae Sang
    Lee, Yunhee
    Myong, Jun-Pyo
    Ha, U-Syn
    WORLD JOURNAL OF UROLOGY, 2022, 40 (12) : 3043 - 3048
  • [38] Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort - Comment
    Colli, E
    JOURNAL OF UROLOGY, 2006, 175 (03): : 1022 - 1022
  • [39] Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study
    Chu-Wen Fang
    Cheng-Hsi Liao
    Shih-Chi Wu
    Chih-Hsin Muo
    World Journal of Urology, 2018, 36 : 931 - 938
  • [40] Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study
    Fang, Chu-Wen
    Liao, Cheng-Hsi
    Wu, Shih-Chi
    Muo, Chih-Hsin
    WORLD JOURNAL OF UROLOGY, 2018, 36 (06) : 931 - 938
12345